Download the Case Study
Delivering Large-Scale Phase III Obesity Program with Speed, Quality, and Patient-Centric Execution
Delivering Large-Scale Phase III Obesity Program with Speed, Quality, and Patient-Centric Execution
Delivering Large-Scale Phase III Obesity Program with Speed, Quality, and Patient-Centric Execution
Scaling a Phase III obesity program requires speed, precision, and a patient-centric approach. In a pivotal GLP-1 program spanning ~5,700 participants and ~150 sites, Medpace supported rapid study startup, accelerated enrollment, proactive patient retention and consistent dose management.
Explore the case study to see how an integrated, patient-centric approach helped navigate the operational complexity of a large-scale obesity program.
Making the Complex Seamless in
Obesity Clinical Development
With decades of phase I-IV metabolic experience and access to in-house and external data streams, Medpace supports the development and execution of rare to large global obesity trials. Medpace has medical, operations, and regulatory staff who understand the complexities of obesity trials from the perspective of the Sponsor, the patients, the clinical investigator, the scientific leader, and the reviewer at the regulatory agencies. Our matured relationships with global thought leaders, investigative sites, the Medpace global ‘flagship’ metabolic site network, and patient advocacy groups, as well as knowledge of effective patient retention strategies, ensure efficient and quality patient enrollment which is key to the success of these programs.
